Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Venus Remedies Ltd Stock Analysis

Small Cap
Evaluated by 830 users | BSE: 526953 | NSE: VENUSREM |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 15.96%13.93%12.65%12.12%4.44%3.65%0.94%-0.86%-1.08%0.63%10.03%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 363410469542464418400372322339548566
Y-o-Y Gr. Rt.-12.9%14.4%15.6%-14.3%-9.9%-4.4%-6.9%-13.6%5.4%61.5%-
Adjusted EPS (Rs.) 50.648.2854.3356.184.441.47-15.02-24.94-20.08-4.5833.0761.05
Y-o-Y Gr. Rt.--4.6%12.5%3.4%-92.1%-66.9%-1121.8%NANANANA-
Book Value per Share (Rs.) 254.92306.18355.1403.43399.13382.47314.92293.23269.42262.01313.18325.64
Adjusted Net Profit 46.24757.364.35.11.7-18.5-30.8-24.8-5.740.882
Net Op. Cash Flow (Rs. Cr.) 37.441.752.252.767.846.958.931.245.377.6133-
Debt to Cash Flow from Ops 55.295.25.484.737.155.299.846.572.840.39-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Venus Remedies Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 3.3%5.6%13.8%61.5%
Adjusted EPS -4.1%86.4%NANA
Book Value per Share 0.3-3.92.219.5
Share Price 10.2% 36.3% 107.1% 224.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 22.6417.2816.6915.291.110.38-4.49-8.2-7.14-1.7211.2819.11
Operating Profit Margin (%) 24.8125.125.6325.5219.2219.412.6810.610.112.039.8111.8
Net Profit Margin (%) 12.7211.4812.2211.871.090.4-4.63-8.27-7.7-1.677.4514.43
Debt to Equity 0.80.740.720.630.70.770.80.850.90.680.130.09
Working Capital Days 133152177197251270270285337338189131
Cash Conversion Cycle 92991061071351531521531701477075
Loading price chart...
Entity Percentage Holding
Promoters 40.81%
Institutions 0.10%
Non-Institutions 59.09%
Pledged *100.00100.00100.00100.00100.00100.0095.4818.7415.220.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Venus Remedies Ltd's earnings have grown by 86.4%, whereas share price has appreciated 36.3% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Venus Remedies Ltd share price has appreciated 10.2% annually (CAGR) over the past ten years.

Data is not available for this company.

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefelosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Presently, the company has successfully made its presence in the markets of Philippines, Thailand, Malaysia, Cambodia, Burma, Vietnam, Sri Lanka, Pakistan, Bangladesh, Nepal, Uganda, Kenya, Botswana, Zimbabwe, Sudan, Mauritius, Yemen, Iraq, Russia, Belarus, Ukraine, Costa Rica, Venezuela, Guatemala, Peru, Colombia, Ecuador, Syria, Yeman, Togo, Saudi Arbia and Iraq.

Company has entered into strategic alliances with various pharmaceutical companies to launch its R&D based specialty products. It has tie-ups with companies namely IPCA Laboratories, Elder Pharmaceuticals, Shreya Lifesciences, Cadila Healthcare, Glenmark Pharmaceuticals, Marksans Pharma, Indoco Remedies, Karle Health Sciences, Lupin and Jagsonpal Pharmaceuticals.

Company also conducts in-house research and development activities that focuses Formulation Development, NDDS (Novel Drug Delivery System), new formulations of off patented chemicals and analytical and chemical research.

Products

The company is engaged in manufacturing products catering various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties, Intravenous Products, Vials/Lyophilized Injectables, Pre-Filled Syringes, Hormones, Ampoules and Biological Products.

Milestone/ Awards

2009
Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa.
Venus Bags Another Product Patent from South Africa for POTENTOX.
2010
Venus Remedies receives GMP Certification from Botswana".
Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits.
The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015.
Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent"
2011
Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.
Venus launches its patented research product ACHNIL” in India.
Venus Remedies wins ""India Manufacturing Excellence Award 2011.
2012
Venus Remedies introduces "Ready-to-Use"" Single Vial Taxedol in India
Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India
The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012.
Venus wins Patent award in Silver Category.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback